Mondego Bio Launches with Series A Funding for AI-Driven Cancer Therapies

Expert Systems Inc. has announced the launch of Mondego Bio, an emerging immuno-oncology company, with Series A funding. Announced in a press release, the new venture is supported by Biovance Capital, Torrey Pines Investment, and OrbiMed.

Mondego Bio is focused on developing a portfolio of first- and best-in-class PTPN2 inhibitors aimed at transforming cancer immunotherapy. These drug candidates have been designed and optimized using Expert Systems' AI/ML-driven molecular design and predictive pharmacology platform, significantly accelerating the path from concept to clinical readiness.

Expert Systems will continue to provide strategic, scientific, and technological support as Mondego Bio advances its pipeline into first-in-human studies. This collaboration underscores Expert Systems' capability to create and scale high-value biotech ventures, reducing early-stage innovation risks for investors and partners.